Alpha-glucosidase inhibitor

Abstract

The invention discloses an alpha-glucosidase inhibitor, which is mainly composed of an unsaturated fatty acid component. The invention also discloses application of the unsaturated fatty acid contained in the alpha-glucosidase inhibitor in prevention or treatment of diabetes and obesity. In the invention, the unsaturated fatty acid component is adopted as the alpha-glucosidase inhibitor, which inhibits decomposition of starch and disaccharides in the small intestine and delays the absorption of glucose, thereby achieving the purposes of preventing or treating diabetes and obesity.

Description

technical field [0001] The invention relates to the field of medicine, in particular to an alpha-glucosidase inhibitor. Background technique [0002] Diabetes mellitus is a common endocrine and metabolic disorder, and it is also a global epidemic disease, and its prevalence is increasing day by day. Epidemiological surveys show that diabetes has become another chronic disease that seriously endangers human health after cardiovascular diseases and tumors. According to statistics, the harm of diabetes to the human body is multifaceted. If the blood sugar is not well controlled for a long time, it will cause damage to various tissues and organs in the body. The main harm is concentrated in the heart, brain, kidney, blood vessels, nerves and skin. [0003] The above types of diabetes include: [0004] 1. Type 1 diabetes mellitus (T1DM) [0005] Also known as insulin-dependent diabetes mellitus (IDDM), its cause is unknown or it is a congenital genetic defect, which causes the...

AI Technical Summary

Problems solved by technology

[0008] (a) Interruption of message transmission after insulin binds to the receptor: Insulin can bind to the receptor normally, but the cells cannot receive the proper information to perform carbohydrate metabolism;

[0009] (b) Defective insulin receptors on the cell: Insulin cannot bind to the receptors or there are not enough receptors so that insulin cannot bind to the receptors and produce an effect

[0023] The α-Glucosidase inhibitors (α-Glucosidase inhibitor) that have been widely used today include Acarbose, Voglibose, Miglitol, etc., but when taking these hypoglycemic drugs, patients will still have some side effects, for example, gastrointestinal reactions. Abdominal distension, abdominal pain, diarrhea, gastrointestinal spasmodic pain, intractable constipation, etc. Others include borborygmus, nausea, vomiting, loss of appetite, fatigue, headache, dizziness, skin itching, skin rash, etc.

Images